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httpObjective: To explore the role of far infrared (FIR) radiation therapy for hemodialysis (HD) access maintenance
after percutaneous transluminal angioplasties (PTA).
Methods: This was a prospective observational study. Eligible patients were those who received repeated PTA
with the last PTA successfully performed within 1 week before the study enrollments. Consecutively enrolled
patients undergoing successful HD treatments after PTA were randomly assigned to the FIR-radiated group or
control group without radiation. FIR-radiated therapy meaning 40-minute radiation at the major lesion site or
anastomosed site three times a week was continued until an end-point deﬁned as dysfunction-driven re-PTA or
the study end was reached.
Results: Of 216 participants analyzed, including 97 with arteriovenous grafts (AVG) (49 FIR-radiated participants
and 48 control participants) and 119 with arteriovenous ﬁstulas (AVF) (69 FIR-radiated participants and 50
control participants), the FIR-radiated therapy compared with free-radiated usual therapy signiﬁcantly enhanced
PTA-unassisted patency at 1 year in the AVG subgroup (16.3% vs. 2.1%; p < .01), but not the AVF subgroup
(25.0% vs. 18.4%; p ¼ .50), and this accounted for the overall improved patency rates (21.4% vs. 10.3%; p ¼ .02).
Conclusions: This study suggests FIR-radiated therapy improves PTA-unassisted patency in patients with AVG
who have undergone previous PTA.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Patency, Percutaneous transluminal angioplastyWhat this study addsThe study provides data regarding far infrared (FIR) radia-
tion therapy on recurrent hemodialysis (HD) access stenosis
that has been treated with balloon angioplasty. The positive
results obtained show that FIR radiation therapy following
balloon angioplasty is beneﬁcial in the case of recurrent HD
access stenosis, especially arteriovenous graft stenosis, in
terms of improving the angioplasty-free patency at 1 year.
The data may be clinically valid for management of recur-
rent HD access stenosis and guidance of FIR radiation
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Vascular access plays an important role in hemodialysis
(HD) treatment through two commonly used forms, an
autogenous arteriovenous ﬁstula (AVF) and a prosthetic
arteriovenous graft (AVG). Vascular access stenosis, which
probably emerges over time, is one of the major causes of
HD access failure. Percutaneous transluminal angioplasty
(PTA) has become a ﬁrst-line modality for treating stenosis-
related access dysfunctions.16 However, development of
neointimal hyperplasia after PTA (post-PTA) results in
vascular restenosis.312 A few studies have been published
that propose materials, devices, and techniques with the
intention to retard the process of neointimal hyperplasia
and improve HD access survival.1319 Among these, the
novel therapy of far infrared (FIR) radiation has been
documented to improve the unassisted patency at 1 year in
the AVF population, possibly through thermal and non-
thermal effects.19 Reported beneﬁcial effects of FIR
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thelial nitric oxide (eNO), inhibition of endothelial inﬂam-
mation, improvement of impaired endothelial function, and
increased skin microcirculation.2025 To the best of our
knowledge, no literature has been published regarding the
impact of post-PTA FIR radiation therapy on patency
outcome. This study was therefore designed to investigate
the effect of post-PTA FIR radiation therapy on unassisted
patency outcome in HD patients who had undergone
repeated PTA.MATERIALS AND METHODS
Patient selection
The study was primarily designed as a single-center, pro-
spective, and randomized study. Eligible recruited patients
were those who had received two or more PTA on the
target lesions at upper extremities, with the last PTA suc-
cessfully performed within the week before patient enroll-
ment. After successful completion of at least 1 week of HD
treatment, the patients with AVF or AVG were consecu-
tively enrolled and randomly assigned to either a post-PTA
FIR radiation group or a control group receiving the usual
form radiation therapy at a 1:1 ratio. Excluded patients
were those who received HD treatments other than three
times a week, who had previously received FIR radiation
therapy, who received implantation of an endovascular
stent, who had multiple lesions that a single radiation ﬁeld
did not cover or the central lesion was considered too deep
to be irradiated, who missed FIR radiation treatments
exceeding 10%, who underwent renal transplantation or
switched to peritoneal dialysis treatments, or who had any
severe disease with an estimated life expectancy of less
than 1 year. Data relevant to baseline characteristics and
patency outcomes were accumulated between groups. The
study was conducted in accordance with the Declaration of
Helsinki and the local regulatory guidelines. The medical
ethics committee of the hospital approved the study pro-
tocol (VGHKS098-CT4-12). Informed consent was obtained
from all participants before beginning the study.PTA before FIR radiation therapy
The participants were referred to our center for angiog-
raphy and PTA as appropriate when the access developed
any of the following referral criteria: (a) dysfunctional ac-
cess signs including abnormal symptoms or physical exam-
ination ﬁndings suggesting anatomic lesions; (b) presence of
decreased ﬂow signs when the inﬂow rate was set at
300 mL/min; (c) increased dynamic intra-access pressure by
25% from initial baseline; or (d) acutely thrombosed access.
A signiﬁcant lesion was deﬁned as a lumen loss of 50% or
more compared with adjacent normal vessel. In the study,
the stenotic lesions were treated with balloon PTA using
normal-pressure balloon catheters (Fox plus PTA catheter;
Abbott, IL, USA) and/or high-pressure balloon catheters
(Conquest PTA balloon dilatation catheter; Bard, Tempe, AZ,
USA) on an outpatient basis. Patients who received vascularstents were excluded from the study. In general, high-
pressure balloon PTA was reserved for lesions refractory
to normal-pressure balloon PTA at the rated burst pressure.
The inﬂated pressure was gradually increased until the
lesion was totally dilated or the pressure reached the level
of rated burst pressure. The double balloon occlusion
technique, previously documented to be safe and effective
for thrombectomy,26 was implemented for salvaging acutely
thrombosed AVGs despite the other techniques for
thrombectomy reported.27 In addition, thromboaspiration
and pharmacologic thrombolysis (urokinase) were
permitted for rescuing acutely thrombosed accesses. Board-
certiﬁed vascular interventionists with 2 to 7 years’ expe-
rience performed all study-related procedures. Two inde-
pendent and experienced physicians interpreted
angiographic ﬁndings and determined procedural ends for
minimization of interobserver bias.
Post-PTA FIR radiation therapy
The therapy was administered in three 40-minute sessions
per week before, during, or after each HD treatment, either
at the HD unit or at our center. The WS TY-101N emitters
(WS Far Infrared Medical Technology Co., Ltd, Taipei,
Taiwan) used for the FIR radiation therapy were positioned
approximately 20 to 25 cm above the skin surface at the site
of the major stenotic lesion or at the venous anastomosed
site for the occluded type in which the major lesion was
undetermined. Irradiating power densities are about 10 and
20 mWatt/cm2 when a radiator is set at a distance of 30 and
20 cm above the skin surface, respectively. Radiation ther-
apy was continued every week until an end-point was
reached.
Follow-up and endpoints
The target accesses were weekly assessed using the same
criteria mentioned above during the 1-year follow-up. Once
dysfunctional signs and any of referral criteria recurred in
participants with the target accesses, angiography was done
to conﬁrm the need for repeat PTA. When a re-PTA was
performed, the study ended and radiation therapy was
discontinued. Unassisted access patency was deﬁned as the
period between the ﬁrst re-intervention and the initial PTA.
Participants who missed over 10% of radiation treatments,
switched to peritoneal dialysis, received renal trans-
plantation, or were lost to follow-up were excluded from
analysis.
Statistical analysis
All variables were analyzed with SPSS software for Windows
(Version 12.0; SPSS Inc., Chicago, IL, USA). All categorical
data and rates are displayed as percentages and numbers,
and the continuous data are shown as means  standard
deviation. Baseline characteristics and outcome data were
compared between groups using chi-square test or Fisher
exact test for categorical variables, independent Student t
tests for continuous variables, and ManneWhitney U test
for non-normally distributed continuous variables. Kaplane
728 C.-C. Lai et al.Meier survival analysis with log-rank test was used to detect
differences in unassisted patency between groups. A p
value <.05 with two-sided 95% conﬁdence interval was
considered statistically signiﬁcant for all tests.RESULTS
Baseline characteristics
From March 2008 to March 2010, a total of 216 enrolled
participants, 97 with AVG and 119 with AVF, were randomly
assigned to post-PTA FIR radiation therapy or usual form of
radiation therapy at a 1:1 ratio, to create four groups: (1) 49
with AVG receiving post-PTA FIR radiation therapy; (2) 48
with AVG receiving post-PTA usual therapy as control par-
ticipants; (3) 60 with AVF receiving post-PTA FIR radiation
therapy; and (4) 59 with AVF receiving post-PTA usual
therapy as control participants. Unpredictably, nine AVF
control participants asked to cross over to the FIR-radiated
group after the assignments had been made (Fig. 1). During
the follow-up period, one participant died from lung cancer
and another died suddenly in the AVF population. Finally,
68 AVF participants in the FIR-radiated group (Group 3) and
49 AVF controls (Group 4) were analyzed. No patients
missed FIR radiation treatments exceeding 10%, none un-
derwent renal transplantation, and none switched to peri-
toneal dialysis treatment in the course of the study. As
shown in Table 1, baseline characteristics were identical
between groups in the AVF or AVG population.Unassisted patency outcomes
The results are summarized in Table 2. The 118 participants
in Groups 1 and 3, receiving post-PTA FIR radiation therapy,
had signiﬁcantly enhanced unassisted patency rates at 1
year (21.4%, 25/117 vs. 10.3%, 10/97, respectively; p ¼ .04)
compared with the 98 participants in Groups 2 and 4
receiving post-PTA usual therapy. The beneﬁt of post-PTA
FIR radiation therapy was also demonstrated by Kaplane
Meier survival analysis (p ¼ .02) (Fig. 2).
The impact on patency outcome obviously varied be-
tween the AVG and AVF subgroups. In the AVG population,Figure 1. The patient ﬂow chart.post-PTA FIR radiation therapy (Group 1) signiﬁcantly
augmented the unassisted patency rates at 9 months
(28.6%, 14/49 vs. 8.3%, 4/48, respectively; p ¼ .01) and at 1
year (16.3%, 8/49 vs. 2.1%, 1/48, respectively; p ¼ .02)
compared with the usual therapy (Group 2). KaplaneMeier
survival analysis also conﬁrmed the beneﬁt of post-PTA FIR
radiation therapy in terms of improved cumulative inci-
dence of unassisted patency at 1 year (p ¼ .01) (Fig. 3). In
addition, Table 3 shows the results of subgroup analysis of
the AVG population. In the AVF population, post-PTA FIR
radiation therapy (Group 3) did not produce a statistical
difference in unassisted patency rate at 1 year compared
with the usual therapy (Group 4) (25.0%, 17/68 vs. 18.4%,
9/49, respectively; p ¼ .50). The similarity of patency
outcome was also demonstrated by KaplaneMeier analysis
(p ¼ .45) (Fig. 4).
Unassisted patency rates signiﬁcantly differed between
the AVG control participants (Group 2) and AVF control
participants (Group 4). The AVF control participants were
associated with a signiﬁcantly higher rate of unassisted
patency at 1 year compared with the AVG control partici-
pants (18.4%, 9/49 vs. 2.1%, 1/48, respectively; p ¼ .01)
despite a potential difference in baseline characteristics. In
contrast with the control groups, no difference in unassisted
patency rate at 1 year was observed between the AVG FIR-
radiated group (Group 1) and the AVF FIR-radiated group
(Group 3) (16.3%, 8/49, vs. 25.0%, 17/68, respectively;
p ¼ .36 by Fisher exact test).Complications
No patients suffered from radiation-related complications
such as skin burn injuries or allergies.
DISCUSSION
FIR radiation therapy has been reported to improve access
blood ﬂow and unassisted patency in patients with func-
tioning AVFs.19 To the best of our knowledge, this is the ﬁrst
study to investigate the impact of post-PTA FIR radiation
therapy on unassisted patency in HD patients who had
received repeat PTA on recurrent lesions. The study gen-
erates four major ﬁndings: (a) AVF and AVG that have
required more than two PTAs have very poor unassisted 1-
year patency rates; (b) post-PTA FIR radiation therapy
signiﬁcantly improves the unassisted patency at 1 year
compared with the usual form of radiation therapy; (c) the
use of FIR radiation improves the unassisted patency rate in
patients with AVG but not in patients with AVF who have
previously undergone more than two PTA; (d) post-PTA FIR
radiation therapy particularly beneﬁts AVG patients with
age exceeding 70 years, no diabetes, fewer previous PTA,
and non-occlusion type.
The proposed thermal and non-thermal effects of FIR
radiation therapy may delay the progression of vascular
restenosis and prolong the intervention-free survival time.19
FIR radiation emitters generate electromagnetic waves with
wavelengths in the spectral range of 3 to 25 mm (most of 5
to 12 mm and peak at 8.2 mm), which are sufﬁcient for
Table 1. Characteristics of the FIR-radiated group and control group in the AVF and AVG populations.
AVF population (n ¼ 119) AVG population (n ¼ 97)
FIR-radiated group (n ¼ 69) Control group (n ¼ 50) pa FIR-radiated group (n ¼ 49) Control group (n ¼ 48) pa
Age (years) 62.7  10.9 63.1  12.5 .86 67.8  15.7 66.9  9.7 .35
Male/female 32/37 24/26 1.00 18/31 12/36 .27
Hypertension (n) 48 38 .54 34 30 .53
Diabetes (n) 42 28 .71 20 16 .53
Hemodialysis time (years) 4.2  3.5 4.9  4.7 .37 5.7  5.6 5.7  5.1 .83
Duration of access (months) 21.8  23.0 23.5  22.6 .69 20.2  19.1 21.1  22.0 .56
No. of angioplasties at target
access before study of
.46 .80
1 14 15 9 11
2 30 20 19 16
3 or more 25 15 21 21
Presentation:
Stenosis type .39 .19
Elevated pressure ratio 15 6 5 7 .14
Low ﬂow rate 36 29 30 27 .11
Mixed or uncertain 18 15 1 6 .98
Acute occlusion 8 8 .59 18 15
Lesion site: .79
Vein-side lesions 32 26 30 35 .44
Artery-side lesions 17 12 2 2 .43
Multiple lesions 20 12 17 11 .26
Maximal balloon size .14
NP: 4e10 mm (n) 4(5)/5(27)/6(17)/
7(11)/8(8)/9(1)
5(23)/6(14)/7(5)/
8(5)/9(0)/10(3)
5(3)/6(7)/7(21)/8(15)/
9(0)/10(3)
6(3)/7(25)/8(16)/
9(1)/10(3)
.41
HP: 5e8 mm (n) 5(8)/6(6)/7(4)/8(3) 5(6)/6(4)/7(2)/8(2) 6(3)/7(10)/8(8) 6(2)/7(13)/8(7) .58
Angioplasty-related complication 2 1 1.00 1 1 1.00
FIR radiation-related complication 0 0 0 0
Death 1 1 1.00 0 0 e
Loss to follow-up 0 0 e 0 0 e
AVF ¼ arteriovenous ﬁstula; AVG ¼ arteriovenous graft; FIR ¼ far infrared radiation; HP ¼ high pressure; NP ¼ normal pressure.
a Comparison between the FIR-radiated group and control group by chi-square test for categorical variables and by independent Student t test for continuous variables.
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Table 2. PTA-unassisted patency rates in overall, AVF, and AVG populations during 1-year follow-up.
Overall (N ¼ 216) AVF population (n ¼ 119) AVG population (n ¼ 97)
FIR-treated
(n ¼ 118)
Control
(n ¼ 98)
pa FIR-treated
(n ¼ 69)
Control
(n ¼ 50)
pa FIR-treated
(n ¼ 49)
Control
(n ¼ 48)
pa
Unassisted patency
at 3 months 71.2% (84) 56.1% (55) .02 78.3% (54) 64.0% (32) .10 61.2% (30) 47.9% (23) .22
at 6 months 39.0% (46) 31.6% (31) .32 42.0% (29) 38.0% (19) .71 34.7% (17) 25.0% (12) .38
at 9 months 29.9% (35) 18.6% (18) .06 30.1% (21) 28.6% (14) .84 28.6% (14) 8.3% (4) .01
at 12 months 21.4% (25) 10.3% (10) .04 25.0% (17) 18.4% (9) .50 16.3% (8) 2.1% (1) .02
AVF ¼ arteriovenous ﬁstula; AVG ¼ arteriovenous graft; FIR ¼ far infrared radiation; PTA ¼ percutaneous transluminal angioplasty.
a Comparison between the FIR-radiated group and the control group by chi-square test.
730 C.-C. Lai et al.producing both thermal and non-thermal effects.28 The
thermal effects of FIR radiation therapy are generated by
the transfer of heat energy to a depth of 1 to 3 cm in
subcutaneous tissue and by an increase in skin temperature
of up to 4 C.29 Data from animal models have shown that
FIR radiation therapy improves vascular endothelial func-
tion through thermal effects which lead to up-regulation of
endothelial NO synthase (eNOS).30,31 Furthermore, non-
thermal effects considered unique to FIR radiation ther-
apy have been proven to inhibit vascular inﬂammation by
inducing heme oxygenase-1,20 to increase arterial eNOS and
NO production in cardiomyopathic hamsters,21 to promote
microvascular angiogenesis via extracellular signal-regulated
kinase,22 to increase skin microcirculation,20 and to improve
skin wound healing.23 These beneﬁcial effects may partially
account for the superiority of FIR radiation therapy over the
usual therapy with regard to patency outcome, particularly
in the AVG population. Subgroup analysis also provides us
with clues to undergo further investigation.
The prior study by Lin et al. included 145 participants
with functioning AVF who had not received PTA exceeding 3Figure 2. One-year cumulative incidence of PTA-unassisted patency
is shown overall. The KaplaneMeier plot denotes a signiﬁcant
increase in 1-year cumulative incidence of PTA-unassisted patency in
the group receiving FIR-radiated therapy (FIRT) compared
with receiving free-radiation usual therapy after index PTA.months before recruitment.19 Most of them (72.4%, 105/
145) had not received a PTA previously. The difference in
study populations may explain the inconsistent results in
unassisted patency at 1 year. It is not surprising that the
recurrent AVF lesions treated with repeat PTAs responded
poorly to the FIR radiation therapy. The beneﬁcial effects on
vascular access provided by this therapy may have been
partially attenuated or neutralized in the current series. The
ﬁndings imply that the impact of FIR radiation therapy on
unassisted patency varies among groups with functioning
AVF and recurrently PTA-treated AVF. We consider that the
PTA-treated lesions are more likely to accelerate neointimal
hyperplasia and develop access vascular restenosis
requiring re-intervention.46,1417 For the AVF population,
the data, compared with those from the landmark study,
demonstrated the apparently lower rate of unassisted
patency at 1 year for both the FIR-radiated group (25%, 17/
68 vs. 85.9%, 55/64; p < .01) and the control group (14.3%,
7/49 vs. 67.6%, 46/68; p < .01), although the baseline
characteristics were potentially different.19 These ﬁndingsFigure 3. One-year cumulative incidence of PTA-unassisted
patency is demonstrated using KaplaneMeier analysis in partici-
pants with AVG. The cumulative 1-year incidence of PTA-
unassisted patency is signiﬁcantly higher in the FIRT group
compared with the free-radiation control group after index PTA.
Table 3. Subgroup analysis of AVG population in PTA-unassisted patency durations between FIR-radiated group and control group.
Subgroups FIR-radiated group (n ¼ 49) Control group (n ¼ 48) pa
Male 135.6 (n ¼ 18) 106.3 (n ¼ 12) .53
Age > 70 years 163.0 (n ¼ 27) 70.6 (n ¼ 18) <.01
Age > 65 years 165.9 (n ¼ 35) 70.6 (n ¼ 23) .07
Diabetes mellitus 133.9 (n ¼ 20) 129.6 (n ¼ 16) .92
Non-diabetes mellitus 172.8 (n ¼ 29) 93.0 (n ¼ 32) .01
Hypertension 167.6 (n ¼ 34) 113.5 (n ¼ 30) .09
Non-hypertension 132.7 (n ¼ 15) 91.3 (n ¼ 18) .23
1 previous PTA 244.7 (n ¼ 9) 96.3 (n ¼ 11) <.01
2 previous PTA 159.4 (n ¼ 19) 138.4 (n ¼ 16) .66
3 previous PTA 117.0 (n ¼ 21) 84.6 (n ¼ 21) .23
Presentation with elevated VP 154.8 (n ¼ 30) 108.6 (n ¼ 27) .10
Presentation with mixture of elevated VP and low
ﬂow
145.8 (n ¼ 18) 111.9 (n ¼ 15) .48
Vein-side lesion 158.1 (n ¼ 30) 110.1 (n ¼ 35) .10
Multiple lesions 137.9 (n ¼ 17) 107.6 (n ¼ 11) .51
Occlusion type 176.8 (n ¼ 5) 115.7 (n ¼ 7) .56
Non-occlusion (stenosis) type 154.6 (n ¼ 44) 103.4 (n ¼ 41) .03
Presented as the mean of patency days and number of subgroups. AVG ¼ arteriovenous graft; FIR ¼ far infrared radiation;
PTA ¼ percutaneous transluminal angioplasty; VP: venous pressure.
a Comparison between the FIR-radiated group and the control group by chi-square test.
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AVF which function well or have not received repeat PTA
yet, with the consideration of improving unassisted patency.
On the other hand, the unassisted patency rate at 1 year
unsurprisingly appeared higher in the AVF control partici-
pants than in the AVG control participants who received
PTA alone.36 Nevertheless, our data show that the patency
rates were the same for the AVF and AVG groups receiving
post-PTA FIR radiation therapy. The ﬁndings reveal that
post-PTA FIR radiation therapy may narrow the gap in
patency outcomes between the AVF and AVG groups. TheFigure 4. One-year cumulative incidence of PTA-unassisted
patency is expressed using KaplaneMeier analysis in participants
with AVF. The cumulative 1-year incidences of PTA-unassisted
patency are equal between the FIRT group and the free-
radiation control group (p ¼ .45).mechanism of the ﬁndings is not clear. We infer that vari-
ations in vessel size, capacity for producing NO, or suscep-
tibility to NO may potentially have contributed to the
results. At the least, we can conclude that the application of
non-invasive FIR radiation therapy to HD patients with
functioning AVF and even with recurrently PTA-treated AVG
is safe and clinically beneﬁcial. Although it should be noted
that the low mortality rate in the study may be caused by
patient selection excluding severe diseases.Limitations
A few limitations should be emphasized in the study. (a)
Dysfunction-driven referral is not the ideal or even the most
accurate model for selecting patients with target access
restenosis. For example, a non-radiated lesion may occur.
(b) It is very difﬁcult to quantify, standardize, and formalize
the FIR radiation therapy. This may lead to inequality of the
therapy among groups. (c) Detailed lesion properties, HD
parameters, and PTA procedures were not considered in the
study. They potentially affected the patency outcomes. (d)
The study is limited to a small number of participants un-
dergoing repeat PTA at a single center. The results are not
generalized to all kinds of HD patients.CONCLUSION
The data show that post-PTA FIR radiation therapy is safe
and effective, and improves PTA-free HD access patency,
especially in the AVG series. This study suggests that this
form of radiation therapy may be regarded as a helpful tool
after PTA in terms of prolonged unassisted patency.
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